Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit to Buy RedPath Integrated Pathology

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics said today that it has agreed to buy personalized diagnostics company RedPath Integrated Pathology in a deal that could be worth a total of $32 million.

Paris-based ExonHit plans to buy RedPath, a developer of DNA-based cancer tests, for $12.5 million upfront, another $10 million in stock, and for sales milestone payments that could total another $9.5 million.

RedPath, which is headquartered in Pittsburgh, Penn., has launched the PathFinderTG molecular diagnostic assay for pancreatic cancer, and it is developing another test to differentiate primary from metastasis tumors. RedPath also has two testing service programs in late-stage development and several earlier-stage development programs also focused on oncology testing, ExonHit said.

"The acquisition of RedPath is a significant milestone in ExonHit’s strategy to become an internationally recognized player in molecular diagnostics," Loic Maurel, president of ExonHit's management board, said in a statement.

Maurel said that the deal will strengthen ExonHit’s US presence, which he said represents around 55 percent of the molecular diagnostics market. He also said that the acquisition “will give ExonHit a new dimension, with an innovative offering in oncology, the fastest-growing segment in molecular diagnostics.”

Integrating RedPath’s DNA technology with ExonHit’s RNA-based platform business “will allow for the possibility of more accurate diagnostic tests” and will give the firm a stronger IP position, ExonHit said.

The deal, which is subject to approval by ExonHit’s shareholders at an upcoming meeting, is expected to close before mid-July.

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.